(EN) The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with a CDK7 inhibitor conforming to structural Formula (I), (la), a species thereof, or a specified form thereof (as described herein), either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy). Patients are identified based on one or more features (e.g., gene copy number or expression level) of certain biomarkers (e.g., RB1 or another member of the E2F pathway). In addition, the present invention relates to methods of treating an identified patient with a compound conforming to structural Formula (I), (la), a species thereof, or a specified form thereof, either alone or in combination with a second therapeutic agent. In another aspect, the present invention features kits including instructions for treating a patient identified as described herein.
(ZH) 本发明涉及鉴定患有多种类型癌症的患者的方法,当单独施用或使用或与第二治疗剂(例如,另一种抗癌疗法)组合时这些患者更可能对用符合结构式(I)、(Ia)、其种类或其指定形式(如本文所述)的CDK7抑制剂的治疗有响应。基于某些生物标志物(例如,RB1或E2F途径的另一成员)的一个或多个特征(例如,基因拷贝数或表达水平)来鉴定患者。此外,本发明涉及用符合结构式(I)、(Ia)、其种类或其指定形式的化合物单独或与第二治疗剂组合治疗经鉴定的患者的方法。在另一方面,本发明的特征在于包括用于治疗如本文所述鉴定的患者的说明书的试剂盒。